secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001104659-24-004966
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise reports $318.4M cash, outlines 2024 milestones, terminates ATM program
-------------------------------------------------------------------------------

- Preliminary cash, equivalents and marketable securities of $318.4M as of Dec 31, 2023; shares outstanding 70.5M.
- EDG-5506: 24-month ARCH data (Becker MD) in H1 2024; 1-year CANYON data in Q4 2024.
- EDG-5506: Phase 2 DUNE exercise data (Becker, LGMD, McArdle) in H1 2024; 3-month LYNX data (Duchenne) in H1 2024.
- EDG-7500 Phase 1 data in healthy volunteers and oHCM patients expected Q3 2024.
- Terminated ATM equity program with BofA Securities; no further sales under existing prospectus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924004966/0001104659-24-004966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924004966/tm243583d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-004966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer